Paolo Tarantino
Overview
Explore the profile of Paolo Tarantino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waks A, Tarantino P, Chen E, Freedman R, Lin N, Tayob N, et al.
Cancer
. 2025 Jan;
131(3):e35729.
PMID: 39887682
Background: The risk of recurrence in patients with small, lymph node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancers untreated with adjuvant chemotherapy/HER2-directed therapy is uncertain. To investigate this,...
2.
3.
Pecci F, Tarantino P
Transl Lung Cancer Res
. 2025 Jan;
13(12):3819-3823.
PMID: 39830766
No abstract available.
4.
OMeara T, Tarantino P, Morganti S, Schlam I, Garrido-Castro A, Tolaney S
Curr Oncol Rep
. 2025 Jan;
27(1):68-79.
PMID: 39786525
Purpose Of Review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine...
5.
Lamont E, Stein E, Tarantino P, Tolaney S, Ahlberg C, Chinnathambu K, et al.
Breast Cancer Res Treat
. 2024 Dec;
210(1):11-14.
PMID: 39707103
The therapeutic importance of subsetting patients with HER2-negative breast cancer according to their tumors' cellular HER2 expression (e.g., HER2-low vs. HER2-0) is relatively new, stemming from the dramatic results of...
6.
Bergerot C, Bergerot P, Maues J, Segarra-Vazquez B, Mano M, Tarantino P
Ann Palliat Med
. 2024 Dec;
13(6):1550-1551.
PMID: 39632820
No abstract available.
7.
Michelon I, Dacoregio M, Vilbert M, Priantti J, Ernesto do Rego Castro C, Vian L, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241297079.
PMID: 39574495
Background: Until recently, targeted therapies have failed to benefit patients with human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC). Nevertheless, antibody-drug conjugates (ADCs) have reshaped their prognosis. Objectives:...
8.
Pan S, Gadrey J, Sammons S, Lin N, Tolaney S, Tarantino P, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241292266.
PMID: 39529890
Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local...
9.
Colombo R, Tarantino P, Rich J, LoRusso P, de Vries E
Cancer Discov
. 2024 Oct;
14(11):2089-2108.
PMID: 39439290
Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical...
10.
Tarantino P, Tolaney S
Lancet
. 2024 Oct;
404(10461):1376-1378.
PMID: 39396338
No abstract available.